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Abstract
Background: Platelet aggregation monitoring in diabetic patients treated with coronary interventions (PCI) for an
acute coronary syndrome (ACS) is a promising way of optimizing treatment and outcomes in this high risk group.
The aim of the study was to verify whether clopidogrel response measured by Multiplate analyzer (ADPtest) in
diabetic ACS patients treated with PCI predicts the risk of stent thrombosis or cardiovascular mortality and bleeding.
Methods: Into this prospective, observational study 206 elective PCI patients were enrolled. Two cutoff points of
ADPtest were used in analysis to divide patients into groups. One (345 AU x min) was calculated based on ROC
curve analysis; this cutoff provided the best ROC curve fit, although it did not reach statistical significance. The
other (468 AU x min) was accepted based on the consensus of the Working Group on On-Treatment Platelet
Reactivity. The risk of stent thrombosis and mortality was assessed using Cox regression analysis and Kaplan-Meier
curves.
Results: The risk of stent thrombosis was higher in the group of patients with impaired clopidogrel response for
either cutoff value (for >354 AU x min - HR 12.33; 95% CI 2.49–61.1; P = 0.002). Cardiovascular mortality was also
higher in the impaired clopidogrel response group (for >354 AU x min - HR 10.58; 95% CI 2.05–54.58; P = 0.005).
We did not find a clear relation of increased clopidogrel response to the risk of bleeding.
Conclusions: The results of this study show that in diabetic ACS patient group treated with PCI an impaired
platelet response to clopidogrel measured by the Multiplate analyzer results in increased risk of stent thrombosis
and cardiac death.
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Background
Acute coronary syndromes (ACS) in diabetic patients are
associated with increased overall risk compared to the
general ACS population despite unquestionable advances
in treating these patients [1]. Most patients are treated
with percuatenous intervention (PCI) with stent implant-
ation [2] while a minority are referred for coronary artery
bypass grafting (CABG). Still, recurrent ischemia is a
common clinical phenomenon among patients with dia-
betes [3]. For some time now newer antiplatelet agents,
such as ticagrelor and prasugrel, have been preferentially
advocated for use in ACS instead of clopidogrel. However,
in many centers worldwide the routinely used antiplatelet
agent in most settings is still clopidogrel [4, 5]. It is gener-
ally recognized that many patients exhibit diminished
response to clopidogrel [6]. This problem may be and
probably is even more important in diabetic ACS patients
than in the unselected patient population treated with PCI
[7, 8]. The clinical relevance of inadequate reduction of
platelet aggregation by antiplatelet agents has now been a
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matter of debate for some years [9–15]. Many observa-
tional studies show it to be of paramount importance,
while some randomized trials are much less conclusive
[16–19].
There are several methods of assessing platelet aggre-
gation accepted for clinical use, such as Verify Now
(Accriva Diagnostics, San Diego, CA, USA), Multiplate
(Roche Diagnostics, Rotkreuz, Switzerland), VASP
(Diagnostica Stago, Asnieres sur Seine, France) and
some others, less standardized [20–22]. Based on avail-
able evidence from randomized trials none of these
methods is currently recommended for routine clinical
use as the efficacy of routine platelet function tests for
guiding the treatment has not been confirmed [23, 24].
Most studies examining platelet aggregation, either
ADP or aspirin induced, were done in cohorts of stable
coronary artery disease (CAD) patients after elective
PCI procedures or in unselected all-comer populations
[25, 26]. There are less studies in patients with ACS
and the data on diabetic patients is mostly derived from
subgroup analyses of large all-comer studies [27–30].
Hence, the aim of the present study was to prospectively
assess whether the degree of platelet aggregation inhib-
ition in a high risk population of diabetic ACS patients on
clopidogrel, treated with PCI, affects outcome. The clinical
outcome endpoints were certain or probable stent throm-
bosis, and bleeding. The study also attempted to elucidate
what is the best cutoff point of aggregations values for pre-
dicting stent thrombosis and bleeding in this population.
Methods
This was a prospective single-center observational study
into which 206 diabetic patients admitted for ACS to the
Institute of Cardiology in Warsaw were enrolled in the
years 2011–2014.
Ethics, consent and permissions: The study protocol
was approved by the local Ethical Review Board and
conducted in accordance with the Declaration of Helsinki.
The study was financed by a National Science Centre
grant NN 402381438.
Consecutive diabetic patients admitted for ACS treated
by successful PCI with stent implantation were in-
cluded. ACS, either STEMI or NSTEMI in case of the
analyzed group, was defined according to the Third
Universal Definition of Myocardial Infarction [31]. Pa-
tients on chronic anticoagulants or medications known to
influence platelet aggregation (such as non-steroid anti-
inflammatory agents or steroids) were excluded.
The primary endpoint of the study was definite or prob-
able stent thrombosis as defined by the Academic Research
Consortium criteria [32] and major or moderate bleeding
as assessed by the GUSTO [33] study criteria.
The secondary endpoints of the study were cardiovas-
cular and overall mortality [34] within one year.
All patients were loaded with 600 mg of clopidogrel ei-
ther prior to or immediately after admission and received
300 mg of aspirin. Angiography and PCI procedures were
performed according to the guidelines of the European
Society of Cardiology [23], with no restriction as to stent
selection, which was left to the discretion of the operator.
Post-dilatation with non-compliant balloons for procedure
optimization was strongly encouraged.
Platelet function assessment
ADP-induced platelet reactivity assessment was performed
directly prior to patient discharge, but no earlier than
in the fourth day after admission. The MEA (multiple
electrode platelet aggregometry) analyzer Multiplate
(Dynabyte, Munich, Germany) was used. The method
has been reapeatedly described previously [35, 36]. In
short, 3 ml of whole blood is collected into a tube con-
taining a direct thrombin inhibitor. After dilution with
saline and agitation while incubating at 37 °C for 3 min
in test cuvettes, 6.4 μmol ADP was added. Platelet aggre-
gation was recorded continuously for 6 min and plotted
against time in AU x min arbitrary units representing the
area under the curve (ADPtest).
The same analyzer was also used to assess platelet re-
sponse to acetylsalicylic acid (ASA). In this case 0.5 mM so-
lution of arachidonic acid was used as agonist (ASPItest).
Study personnel was blinded to the results of the tests –
the test result database was accessed for analysis only after
completing patient follow-up.
Clinical follow-up
Clinical follow-up was done by outpatient visit or tele-
phone interview with the patient at 30 days and 12 months
after the PCI procedure. Data was entered into a computer
database. In case of endpoint or adverse event occurrence
every effort was made to obtain and review source
documentation.
Statistics
Group (sample) size was calculated based on data from
literature such as the risk of ischemic events and per-
centage of patients on clopidogrel showing reduced
response to the drug. The Power and Sample Size
Calculator software was used. We inferred that com-
bined endpoint frequency will be 20% in patients with
inadequate clopidogrel response and 8% in patients
with adequate response. In order to achieve 80% power
(beta 0.8) at the significance level of 0.05 we needed to
include 192 patients. Data was collected on preprinted
forms and entered into a database. Statistical analysis
was performed using SPSS 22 (IBM Corp., USA) and
SAS 9.2 (SAS Institute, Cary, NC, USA) software.
Normally distributed variables were presented as means
and standard deviation, while non-normally distribute
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variables as medians and interquartile range. Categorical
variables were presented as percentages of patients exhi-
biting a given trait. Depending on distribution variables
were analyzed using Student’s t-test or Mann-Whitney U-
test. Chi-square test was used for categorical variables. If
the number of values was less than 5, Fisher’s exact test
was used. Correlation between linear variables was
assessed with Pearson’s test. The analysis of endpoints was
performed using the Kaplan-Meier method (K-M). The
censored observation model was employed. The curves
were compared using the log rank test. In order to eluci-
date variables influencing outcome a Cox proportional
hazard model was used with the forward conditional Wald
variant. A ROC (receiver operator characteristic) curve
analysis was calculated to determine optimal platelet ag-
gregation cutoff values both for thrombotic episodes and
for bleeding. A P value of less than 0.05 was considered
statistically significant in all analyses.
Results
A total of 206 diabetic patients treated with PCI for ACS
were enrolled in the trial, out of which 6 (2.9%) did not
complete follow-up.
The ADP-induced platelet reactivity and the risk of definite
or probable stent thrombosis
During one year follow-up there were 7 cases of definite
stent thrombosis and 1 case of sudden cardiac death
adjudicated as probable stent thrombosis. They occurred
between day 3 and day 360 after the PCI procedure.
The patients were divided into two groups — adequate
response to clopidogrel and impaired response to clopido-
grel based on the ADP-induced platelet aggregation MEA
Multiplate test result. Two cutoff values of ADP-dependent
platelet aggregation as assessed by MEA were analyzed.
The first cutoff point equaling 468 AU x min was
accepted based on previous literature data and the con-
sensus of the Working Group on On-Treatment Platelet
Reactivity. This cutoff point had been elucidated after
analyzing lower risk patient groups (mostly non-diabetic
patients undergoing elective procedures) than in the case
of this paper. This however is the generally accepted
reference cutoff for the Multiplate test.
The second, calculated based on ROC curve analysis,
was 345 AU x min. Despite this being the best fit, the
statistical significance was not reached, possibly due to
low endpoint frequency (ROC curve analysis: sensitivity
75%, specificity 82%, AUC under the ROC curve 0.72,
95% confidence interval 0.47–0.97, P = 0.08; Fig. 1).
However, this cutoff related better to study endpoints in
the analyzed cohort.
The clinical and demographic characteristics of the
studied group are presented in Table 1.
The degree of inhibition of arachidonic acid induced
platelet aggregation (ASPItest) was the only difference
between the two groups of patients — above (impaired re-
sponse) and below (adequate response) the 468 AU x min
cutoff point. The ASPI test result difference remained sta-
tistically significant also when the standard 345 AU x min
cutoff point was used.
Primary endpoint analysis at the ADPtest cutoff point of
468 AUmin
In the case of the advocated reference platelet aggregation
cutoff point of 468 AUmin, the risk of definite stent
thrombosis was not significantly higher in the impaired
clopidogrel response group (HR 4.21; 95% CI 0.82–21.68;
P = 0.086) compared to the remaining group. However,
the risk of definite or probable stent thrombosis was sig-
nificantly higher in the impaired response group (HR 6.40;
95% CI 1.53–26.81; P = 0.011; Fig. 2a).
Primary endpoint analysis at the ADPtest cutoff point of
345 AUmin
When dividing patients into two groups at the cutoff point
of 345 AU x min (based on ROC curve analysis), the risk
of definite stent thrombosis proved to be significantly
higher in the impaired clopidogrel response group (above
345 AU x min; HR 10.15; 95% CI 1.97–52.34; P = 0.006).
Similarly, the risk of definite or probable stent thrombosis
was significantly higher in the impaired response group
(HR 12.33; 95% CI 2.49–61.1; P = 0.002; Fig. 2b).
Risk of stent thrombosis and other potential influencing
factors
In the Cox model analysis there was no increased risk of
stent thrombosis related to the response to aspirin assessed
Fig. 1 ROC curve calculated for ADP-dependent platelet aggregation
as assessed by MEA (ADPtest)
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by MEA, despite this parameter being different between
groups irrespectively of the cutoff point (compare Table 1).
The only other factor related to the risk of definite or prob-
able stent thrombosis was hsCRP serum concentration
(HR 1.11; 95% CI 1.01–1.22; P = 0.03).
None of the other clinical or demographic factors out
of those presented in Table 1 were related to the risk of
stent thrombosis in the Cox model.
The analysis of secondary endpoints
Cardiovascular death within one year occurred in 7 pa-
tients. The risk of cardiovascular death was significantly
higher for patients with ADPtest values above 345 AU x
min compared to the remaining group (Cox regression,
HR 10.58; 95% CI 2.05–54.58; P = 0.005), but not in case
of the cutoff point of 468 AU x min (P = 0.076). Further-
more, the risk of cardiovascular mortality was also higher
Table 1 Clinical and demographic data of the studied group with respect to platelet aggregation assessed by MEA Multiplate
analyzer at the cutoff point of 345 AUmin
ADPtest ADPtest P-value
<345 AU ×min 345≥ AU ×min
n = 160 n = 40
Age (years) (mean ± SD) 66.5 ± 11.1 69.6 ± 10.8 p = 0.084
Male (%) 109 (68%) 29 (72.5%) p = 0.593
STEMI (%) 74 (53%) 20 (50%) p = 0.695
ASPItest (AU x min) 88.9 ± 73.0 173.1 ± 150.0 p < 0.001
Drug eluting stent 132 (94%) 33 (83%) p = 0.911
Stent diameter (mm) (median) 3.0 3.0 p = 0.450
Stent (s) length (mm) 18.0 22.0 p = 0.247
Inflation pressure (atm) (median) 16.0 16.0 p = 0.809
Fibrinogen (mg/dL) (mean ± SD) 451 ± 133 480 ± 138 p = 0.358
LDL (mmol/L) (mean ± SD) 2.83 ± 1.1 2.58 ± 0.9 p = 0.278
Creatinine (umol/L) (mean ± SD) 92.9 ± 34.4 103.4 ± 67.6 p = 0.421
hsCRP (mg/dL) (median) 0.4 0.5 p = 0.396
Platelet count (103/ml) (mean ± SD) 204 ± 60 223 ± 70 p = 0.117
White blood count (103/ml) (mean ± SD) 8.65 8.45 p = 0.793
Hemoglobin (mg/dL) (median) 13.8 12.8 p = 0.067
Insulin therapy 46 (33%) 15 (38%) P = 0.293
Fig. 2 a Hazard ratio values of stent thrombosis (as described in the Figure) plotted as HR with 95% confidence intervals for standard MEA cutoff
value of 468 AUmin; Inset (b) Hazard ratio values of stent thrombosis and cardiovascular mortality (as described in the Figure) for the cutoff of 345
AUmin that allowed for better risk stratification in the studied cohort
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when the ADPtest was used as a linear variable (HR 1.002;
95% CI 1.0001–1.005; P = 0.04).
Overall, 11 patients died during the one-year follow-
up. The risk of any-cause death was significantly higher
only in case of patients with ADPtest values above
345 AU x min (HR 3.48; 95% CI 1.06–11.39; P = 0.04)
compared to the remaining group.
Bleeding
Major bleeding as defined by GUSTO II criteria occurred
in 5 patients, while major or moderate bleeding in 24 pa-
tients. Based on ROC curve analysis for ADP-induced
platelet aggregation and major or moderate bleeding, the
best cutoff point discriminating the population at risk for
bleeding was calculated. The MEA aggregation value of
278 AUmin proved the best cutoff point for bleeding in
this population (sensitivity 88%, specificity 42%; ROC
curve AUC 0.61, 95% CI 0.51–0.72; P = 0.034). However,
in the Cox proportional hazards model neither the cutoff
point of 278 AU x min nor the cutoff point used for unse-
lected groups in earlier literature (188 AU x min) was
significantly related to increased bleeding risk.
Discussion
In this prospective observational study we analyzed the
risk of stent thrombosis and bleeding in diabetic pa-
tients presenting with an acute coronary syndrome and
pretreated with clopidogrel and aspirin before PCI. The
relative risk was assessed in relation to the extent of
ADP-induced platelet aggregation measured by MEA
Multiplate analyzer.
We found that increased platelet reactivity (or inad-
equate platelet inhibition) in patients on clopidogrel is
related to increased risk of stent thrombosis and cardio-
vascular mortality within one year. In the studied cohort,
the optimal discriminating cutoff point of platelet reactiv-
ity above which the risk of stent thrombosis is higher was
found to be 345 AU x min. The optimal cutoff point for
the risk of bleeding was, in turn, 278 AU x min.
To date, the clinical implications of platelet reactivity
in patients after PCI were assessed in numerous studies
using a number of different methods, also the MEA
Multiplate analyzer [37–39]. Most of the studied patient
cohorts consisted of elective low stent thrombosis risk
patients or unselected all-comer PCI patients [40–42].
These and other prior studies suggest that the risk of
stent thrombosis is highest in acute coronary syndrome
patients, while diabetes is an additional important con-
comitant condition increasing this risk [43–50].
Observational studies in elective patients, consecutive
patient cohorts and the several ACS patient groups,
with few exceptions, quite uniformly showed an increased
risk of stent thrombosis in patients with inadequate inhib-
ition of platelet aggregation [51–56]. Different methods of
laboratory assessment of platelet aggregation were used
with the MEA Multiplate method repeatedly showing
consistent results across several studies [20, 35, 57].
This evidence spurred randomized trials that have to
date failed to confirm the relationship of platelet aggre-
gation values assessed by laboratory methods and stent
thrombosis. The results of several such trials have been
published. One of them was a subgroup study within the
TRILOGY-ACS trial [58], where conservatively treated pa-
tients had platelet reactivity assessed with the VerifyNow
assay. No difference was found between patients treated
with clopidogrel or more aggressively – with prasugrel. In
other studies, such as the GRAVITAS, ARCTIC and
TRIGGER-PCI [16, 59–62], platelet reactivity was assessed
using different methods in patients after PCI procedures,
on different treatment regimens, but the extent of platelet
inhibition did not translate into a difference in the risk
of stent thrombosis or ischemic events. Two trials, a
non-randomized MADONNA study [63] and the small
randomized study by Hazarbasanova et al. [29] showed
that modifying therapy based on platelet aggregation
assessment using the Multiplate analyzer might bear on
outcome.
The present study was undertaken as we felt there was
lack of direct specific data concerning platelet reactivity
and outcome in high risk populations and because of
conflicting evidence of the above-mentioned studies.
Despite enrolling a comparatively small cohort and
relatively few occurrences of primary endpoint we have
shown that increased platelet reactivity in clopidogrel
treated diabetic ACS patients after PCI is related to in-
creased risk of stent thrombosis. The optimal cutoff
point, above which platelet reactivity may be considered
overt and related to stent thrombosis in the studied co-
hort was 345 AU x min, less than the generally accepted
cutoff elucidated in earlier studies. However, also the
standard cutoff of 468 AU x min allowed to discriminate
the group of patients at increased risk for stent throm-
bosis. It must be noted that this lower cutoff, although
providing better risk stratification did not reach signifi-
cance in ROC curve analysis. The difference between
the optimal cutoff between this and earlier studies must
therefore be considered an approximation and is most
probably the effect of different cohorts studied. In most
trials to date the majority of enrolled patients were low
risk patients. In this study of diabetic patients presenting
with ACS the extent of platelet inhibition in order to
avoid stent thrombosis may be expected to be higher
[comp. 30]. The study also showed that patients with
higher ADP-induced platelet reactivity on clopidogrel
also show diminished response to aspirin [comp. 26].
We have not, however, seen an increase in the risk of
stent thrombosis in relation to arachidonic acid induced
platelet reactivity alone.
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Decreased platelet aggregation invariably results in an
increase of bleeding risk as has been repeatedly reported
in previous studies [35, 64, 65]. In the analyzed cohort
one may reasonably expect both increased stent throm-
bosis and increased bleeding risk compared to unse-
lected populations. This was confirmed by finding that
the optimal cutoff point for increased bleeding in the
studied group was 278 AU x min – higher than the
“standard” cutoff for bleeding of 188 AU x min eluci-
dated in previous studies. However, we did not find a
clear relation of this cutoff to the risk of bleeding.
Based on the data acquired in the study one may think
that the therapeutic window for clopidogrel assessed
with the MEA Multiplate analyzer is more narrow for
our study group than for an unselected lower risk cohort
of patients after PCI. Newer antiplatelet drugs, such as
prasugrel and ticagrelor act more uniformly than clopi-
dogrel and provide greater inhibition of platelet aggrega-
tion. Therefore, as clinical data from other studies show
[41, 44], in a high risk population such as the one ana-
lyzed, they provide better protection against stent
thrombosis at the cost of greater bleeding risk. Platelet
function monitoring using, for example, the MEA Multi-
plate method in high risk cohorts, could lead to a reduc-
tion in bleeding without unduly increasing the risk of
stent thrombosis. Such monitored therapy need not be
confined just to one antiplatelet drug and should allow
for modifying therapy if necessary [66]. This approach
requires confirmation in randomized trials, especially
since there may be several seemingly attractive strategies
of monitored antiplatelet therapy.
Study limitations
The major inherent limitation of this study is its observa-
tional character, not allowing for causal analysis. The
study cohort is relatively small. The primary study end-
point occurred in only 8 patients which precluded mean-
ingful multifactorial analysis. On the other hand, apart
from ADP-induced platelet aggregation, practically no
other analyzed factors correlated with increased risk of
stent thrombosis upon single factor analysis, so it may be
considered an independent association. Platelet reactivity
was measured only once in every patient, but at a period
where drug effect should be full. However, the absence of
repeated measurements would fail to identify patients
who stopped taking the drug despite recommendations.
Patients in this study were treated with clopidogrel, which
at the time of study commencement was the only rou-
tinely used antiplatelet drug in our country. At present,
newer antiplatelet agents are preferentially recommended
that inhibit platelet aggregation more profoundly, but
their use is still not dominant in most areas. It is difficult
to predict how they would influence study outcomes as
far as stent thrombosis and bleeding are concerned.
Conclusions
This work shows that in a high risk population of patients
with ACS and diabetes treated with stent implantation
and receiving clopidogrel, higher on-treatment platelet
reactivity is related to increased risk of stent thrombosis at
1-year follow-up. Whether platelet reactivity-guided ther-
apy may decrease the risk of stent thrombosis and patient
prognosis must be resolved in randomized trials, a few of
which are already underway.
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